Society for Pediatric Pain Medicine
Better Care for Children in Pain

The Society for Pediatric Pain Medicine (SPPM) aims to advance the quality of anesthesia care and the alleviation of pain-related conditions in children.

Member Menu

  • Member Login
  • Forgot Password?
  • Join
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
MAIN MENUMAIN MENU
  • Home
  • About
    • Vision Statement
    • Board of Directors
    • Committees
      • Advocacy Committee
      • Communications Committee
      • Education Committee
      • Finance & Membership Committee
      • Research Committee
    • Special Interests Groups (SIGs)
      • Interdisciplinary Chronic Pain Treatment (ICPT) SIG
      • Special Interest Group: Creating and Maintaining Pediatric Acute Pain Services
      • SPA-SPPM Integrative Medicine SIG
      • SPA-SPPM Ultrasound Regional Anesthesia and Point-of-Care Ultrasound SIG (Ult-RA POCUS SIG)
    • SPPM Bylaws
    • FAQs
    • Contact
  • Meetings
    • Upcoming Meetings
    • Past Meetings
    • Other Meetings
    • Exhibitor Information
  • Education
    • Questions of the Month
    • SPPM Visual Pearls
    • Poll of the Month Archives
    • Featured Lectures
    • Case Reports
    • Books for Clinicians
  • Membership
    • Member Benefits
    • Membership Classifications
    • New Member Spotlight
    • Renew Your Dues
    • Join Now
  • Resources
    • SPPM Young Investigator Research Award
    • SPPM Innovative Research Award
    • Latest News
    • Newsletters
    • COVID-19 Resources
    • Publications
    • Job Postings
    • Links of Interest
  • Patients & Families
    • Useful Links
    • Books for Patients and Families
    • Mobile Apps
    • FAQs
  • Trainees
    • Pediatric Chronic Pain Fellowship Programs
    • Pediatric Acute Pain/Regional Anesthesia Fellowship Programs

Question of the Month – June 2021

{“questions”:{“zf4ni”:{“id”:”zf4ni”,”mediaType”:”image”,”answerType”:”text”,”imageCredit”:””,”image”:””,”imageId”:””,”video”:””,”imagePlaceholder”:””,”imagePlaceholderId”:””,”title”:”June’s Question Submitted By:\r\n \r\nThomas Spain, MD, MPH \r\nAssociate Professor UT Southwestern \r\nChildren’s Medical Center Dallas \r\n\r\n\r\nCase History: \r\nYou are called to the ED to evaluate a 16-year-old male with a severe headache. The patient has a history of testicular germ cell tumor diagnosed two years ago and is s\/p surgical resection and chemotherapy. Today he complains of a 10\/10 pulsating pain in the right temporal region. As you enter the patient\u2019s room, you notice that all the lights are off. The patient\u2019s mom quickly greets you at the door, whispering as she introduces herself, she provides you with some further history. You note that the patient is resting in bed with a cold rag over his eyes with a nearby emesis basin filled with vomitus. Mom reports that the patient started experiencing similar headache episodes 6 months ago. He had an ER visit three weeks ago where he was treated with Benadryl, Compazine, and Toradol with limited benefit. He was then admitted for three days for treatment with DHE that was effective, but his headache returned after 48 hours. Mom is asking if something different can be used to help her child. \r\n\r\nBased on the current literature, which of the following is true?\r\n”,”desc”:””,”hint”:””,”answers”:{“7fzfb”:{“id”:”7fzfb”,”image”:””,”imageId”:””,”title”:”A.\tPropofol has more rebound headaches and a longer length of stay than standard therapy. “},”e9y6d”:{“id”:”e9y6d”,”image”:””,”imageId”:””,”title”:”B.\tA RCT in adults concluded that propofol can be used for management of acute migraines with similar rates of recurrence in the propofol group compared to the Sumatriptan group. “},”s2jcb”:{“id”:”s2jcb”,”image”:””,”imageId”:””,”title”:”C.\tA case series of 8 patients showed significant reduction in pain scores after receiving propofol in patients who failed a combination of triptans, opioids, NSAIDs, or steroids.”,”isCorrect”:”1″},”slaec”:{“id”:”slaec”,”image”:””,”imageId”:””,”title”:”D.\tPropofol works by blocking the Na+ channels in the CNS and therefore limits the transmission of pain.”}}}},”results”:{“71bem”:{“id”:”71bem”,”title”:””,”image”:””,”imageId”:””,”min”:”0″,”max”:”1″,”desc”:”Correct Answer is C. A case series of 8 patients showed significant reduction in pain scores after receiving propofol in patients who failed a combination of triptans, opioids, NSAIDs, or steroids \r\nRATIONALE: \r\nMigraine headaches can cause severe, disabling pain, leading many patients to present to the Emergency Room (ER) in search of pain relief. Migraines are common in children with prevalence of 5% by age 10 and this increases further during adolescence. The use of propofol for refractory migraines is currently being investigated. A retrospective study on children with migraines showed propofol to be an effective abortive treatment. (1). In another study, even though propofol was not superior to standard therapy, it resulted in fewer rebound headaches and shorter length of stay. (2) A RCT in adults concluded that propofol can be used for management of acute migraines with decreased rates of recurrence in the propofol group compared to the Sumatriptan group. (3) A case series of 8 patients showed significant reduction in pain scores after receiving propofol in patients who failed a combination of triptans, opioids, NSAIDs, or steroids. (4) Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes. \r\nMigraines result from a combination of lifestyle, environmental, and genetic factors. The risk of suffering from migraines is about 50% higher among those who have a first degree relative with migraines. Certain disorders that affect children have been associated with migraines and may represent manifestations of migraine genes in their early years. Ability to diagnose and treat migraines in a timely manner may decrease disability, minimizing days away from school and the negative impact on social life. Preventive treatment includes lifestyle modifications, cognitive behavior therapy and medications. The Pediatric Migraine Disability Assessment (PedMIDAS) is a useful tool in assessing the degree of disability and the response to treatment. \r\n\r\n\r\nREFERENCES: \r\n1.\tGelfand A., Pediatric and adolescent headache. Continuum (MINNEAP MINN), 2018; 24(4): 1108-1136 \r\n2.\tSheridan D.C., Spiro D. M., Nguyen T., Koch T.K., Mackler G.D., Low dose Propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatric Emergency Care, 2012; 28(12): 1293-1296 \r\n3.\tSheridan D.C., Hansen M.L., Lin A.L., Fu R., Meckler G.D., Low dose Propofol for pediatric migraine: A prospective, randomized controlled Trial. Journal of Emergency Medicine. 2018; 54(5):600-606 \r\n4.\tMoshtaghion H., Heiranizadeh N., Rahimdel A., Esmaeili A., Hashemian H., Hekmatimoghaddam S., The efficacy of Propofol vs. subcutaneous Sumatriptan for treatment of acute migraine headaches in the emergency department: A double-blinded clinical trial. Pain practice, 15(8), 701-705.\r\n\r\n\r\n”,”redirect_url”:””}}}

Question of the Month – August 2021

{“questions”:{“ua2ox”:{“id”:”ua2ox”,”mediaType”:”image”,”answerType”:”text”,”imageCredit”:””,”image”:””,”imageId”:””,”video”:””,”imagePlaceholder”:””,”imagePlaceholderId”:””,”title”:”\r\nMembrane stabilizers are commonly used to treat both acute and chronic pain in children and adolescents. Which of the following is the MOST likely mechanism of gabapentin?”,”desc”:””,”hint”:””,”answers”:{“orgb6”:{“id”:”orgb6″,”image”:””,”imageId”:””,”title”:”A. Selective inhibition of GABAB<\/sub> receptors containing the GABAB1a<\/sub> and GABAB2<\/sub> subunits”},”pwhg6″:{“id”:”pwhg6″,”image”:””,”imageId”:””,”title”:”B. Selective inhibition on voltage-gated calcium channels containing the \u03b12\u03b4-1 subunit”,”isCorrect”:”1″},”gq3nj”:{“id”:”gq3nj”,”image”:””,”imageId”:””,”title”:”C. Selective inhibition on voltage-gated sodium channels containing the \u03b12\u03b4-1 subunit”},”5nxh8″:{“id”:”5nxh8″,”image”:””,”imageId”:””,”title”:”D. Selective inhibition on voltage-gated potassium channels containing the \u03b12\u03b4-1 subunit”}}}},”results”:{“azuqm”:{“id”:”azuqm”,”title”:””,”image”:”https:\/\/pedspainmedicine.org\/wp-content\/uploads\/2021\/08\/SPPM-QOM-August-2021.jpg”,”imageId”:”1791″,”min”:”0″,”max”:”1″,”desc”:”Correct Answer: B. Selective inhibition on voltage-gated calcium channels containing the \u03b12\u03b4-1 subunit \r\n\r\nAlthough early proposed mechanisms of gabapentin were interaction by activation of the GABAB<\/sub> receptors containing the GABAB1a<\/sub> and GABAB2<\/sub> subunits, thereby enhancing NMDA current or inhibiting AMPA-receptor-mediated transmission to the spinal cord, more recent studies have instead favored selective inhibition at the \u03b12\u03b4-1 subunit of spinal N-type Ca (2+) channels.\r\n\r\nReferences: \r\n1.\tChen J, Li L, Chen SR, et al. The \u03b12\u03b4-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions. Cell Rep<\/em>. 2018;22(9):2307-2321. doi:10.1016\/j.celrep.2018.02.021 \r\n\r\n2.\tCheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacol Sci. 2006;100(5):471-86. doi: 10.1254\/jphs.cr0050020. Epub 2006 Feb 11. PMID: 16474201. \r\n\r\n3.\tLi G, Li P. (2020, Summer) The use of membrane stabilizers in acute and chronic pain. SPPM Newsletter<\/em>. Retrieved from https:\/\/pedspainmedicine.org\/wp-\r\ncontent\/uploads\/newsletters\/2020\/summer\/nonopioid\/Membrane%20Stabilizers%20.html \r\n\r\n4.\tSills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15;168:107966. doi: 10.1016\/j.neuropharm.2020.107966. Epub 2020 Jan 14. PMID: 32120063. \r\n”,”redirect_url”:””}}}

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11

Upcoming Meeting Information

SPPM 13th Annual Meeting
March 12, 2026
Sheraton Denver Downtown
Denver, CO

 

Join SPPM
Renew
Donate
Get Involved
Upcoming
Job Postings

Copyright © 2025 | Log in | Email: [email protected] | Phone: (804) 282-9780